China-based Autobio Diagnostics Co., Ltd (SHA: 603658) has announced a strategic partnership with South Korea-headquartered Boditech Med Inc. The collaboration, which focuses on the immunoassay field, aims to leverage the respective advantages of both companies in the in vitro diagnostics (IVD) sector to develop the Korean market. No financial details of the partnership were disclosed.
Boditech Med: Background and Market Presence
Boditech Med, founded in 1998, is a leading company in the point-of-care testing (POCT) field. The company made its debut in South Korea in 2015 and has since expanded its product portfolio to cover a wide range of clinical sectors, including cardiovascular disease, infection, endocrine, and digestive system disorders. Boditech Med has obtained marketing approvals in major markets such as the US, European Union, China, South Korea, and Japan, establishing a strong global presence.
Strategic Collaboration and Market Development
The partnership between Autobio Diagnostics and Boditech Med is expected to enhance the development of the Korean market for IVD products. By combining Autobio’s expertise and market reach in China with Boditech Med’s established presence in South Korea, the collaboration aims to introduce innovative diagnostic solutions and improve the accessibility of high-quality IVD products in the region. This strategic move is anticipated to benefit healthcare providers and patients by offering more effective and efficient diagnostic tools.-Fineline Info & Tech
